Faron details clinical plans for MDS drug; Cara to seek 'strategic' options
Plus, news about CSL Vifor, Akebia and Pan Cancer T: Faron gets FDA go-ahead for streamlined registrational path: The company said the regulator “acknowledged the difficulties” of running a controlled...
View ArticleJ&J and Emergent settle Covid contract dispute; Siegfried names new CEO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Johnson & Johnson will hand over $50 million to Emergent to...
View ArticleClik here to view.
Illumina competitor Element Biosciences raises $277M in Series D
Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the company takes on market leader...
View ArticleAbbVie's Humira is still on top, but biosimilars are chipping away at its...
The share of AbbVie’s brand-name version of Humira has dropped to 82% of the total market, 13% less than in March, according to a Samsung report published Thursday. The cracks in AbbVie’s...
View ArticleSenate unanimously passes bipartisan pharma patent bill
The Senate in a unanimous vote Thursday afternoon passed a bill that aims to tackle pharmaceutical patent abuses by limiting the number of patents that companies can assert on any one drug. The bill,...
View ArticleAbbVie asks Supreme Court to reconsider ruling on attorney-client communication
AbbVie is asking the Supreme Court to reconsider a lower court’s ruling that attorney records are fair game in a case involving testosterone med AndroGel. The petition issued Thursday argues that a...
View ArticleRoche's gene therapy biotech Spark is laying off employees, ending some...
Roche’s Spark Therapeutics is letting staffers go and has “discontinued” several early-stage programs, a spokesperson confirmed to Endpoints News. “In May, Spark informed employees in an all-employee...
View ArticleClik here to view.
Mikael Dolsten isn’t the only one moving on from Pfizer; Lilly names interim...
Mikael Dolsten → As we learned on Tuesday, Mikael Dolsten is set to leave — but another Pfizer leader is already gone: Eli Lilly’s radiopharma partner Aktis Oncology has welcomed Akos Czibere as CMO....
View ArticleImmutep’s LAG-3 drug scores in Phase 2b head and neck cancer test
Immutep’s protein-based cancer treatment has succeeded in a mid-stage study in patients with head and neck squamous cell carcinoma, spurring discussions with regulators on a path forward. The Phase 2b...
View ArticleIdeaya raises $302M; AbbVie to seek approval in giant cell arteritis
Ideaya closes $302.4M raise: The cash came in higher than expected after Ideaya said earlier this week it planned for a $263 million offering. On Monday, Ideaya presented Phase 2 data for a drug...
View ArticleClik here to view.
Four key takeaways for biopharma from Labour’s win in the UK election
The UK’s center-left Labour Party won a landslide victory at last week’s general election, ending the center-right Conservative government’s 14 years in office. With new faces at the helm, UK biotech...
View ArticleMetagenomi science chief departs, just a few months after IPO
The chief scientific officer at gene editing company Metagenomi is out, the company confirmed to Endpoints News. “As of yesterday, I have parted ways with Metagenomi by mutual agreement,” CSO Luis...
View ArticleHow SCOTUS' decision in Chevron could change the way the FDA regulates biopharma
The Supreme Court’s decision late last month to overrule a decades-old legal doctrine will have major ramifications for the FDA and the biopharma industry it regulates. Legal scholars warn that the...
View ArticleTwo healthcare SPACs go public, with several more on the hunt for deals
The blank-check acquisition companies Launch One Acquisition and SIM Acquisition went public this week, a signal that the healthcare SPAC trend might not be totally dead. On Friday, Launch One began...
View ArticleClik here to view.
Indivior axes schizophrenia drug and shrinks revenue guidance
Indivior’s shares $INDV have lost nearly a third of their value this week, following the company’s announcement Tuesday that it was shelving a schizophrenia drug and had revised down its 2024 revenue...
View ArticleLilly says lupus drug dropped from pipeline failed to show efficacy
An experimental BTLA agonist that Eli Lilly cut from its pipeline for lupus late last year failed to show strong enough efficacy in a mid-stage trial, the company confirmed to Endpoints News. The...
View ArticleDeep dive on pay packages; Lilly strikes $3.2B buyout; Pfizer’s R&D head to...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleArtiva aims for $116M in second attempt at IPO to boost NK cell therapy pipeline
Clinical-stage cell therapy developer Artiva Biotherapeutics will seek about $116 million in net proceeds from its proposed initial public offering, according to an updated SEC document on Monday...
View ArticleClik here to view.
Updated: Lexeo Therapeutics' gene therapy shows potential for Friedreich's...
Lexeo Therapeutics thinks its gene therapy has the potential for accelerated approval following positive interim data from two early-stage studies, the company announced Monday. Executives say the data...
View ArticleEvofem inks women’s health deal; AusperBio brings in $37M
Plus, news about Enveric, Aries Science, LENZ, MediWound and Destiny Pharma: Evofem acquires antimicrobial: The contraceptive maker is buying Lupin’s US commercial women’s health specialty business for...
View Article